From April 2021 to December 2021, 50 pregnant women who received intro fertilization (IVF) will be recuited. Among them, 25 of them would like to take Chinese medicine from the 2nd week after embryo transfer (intervention group), while the remaining 25 will not intake Chinese medicine (control group). Blood and feces samples will be collected in the early morning of the 4th and 6th week after embryo transfer to detect 16S DNA sequences in feces, plasma metabolites, and whole blood transcriptomics.

开始日期2020-05-01

申办/合作机构

Shanghai Meiji Health Science and Technology Co., Ltd.

100 项与保胎丸相关的临床结果

登录后查看更多信息

100 项与保胎丸相关的转化医学

登录后查看更多信息

100 项与保胎丸相关的专利（医药）

登录后查看更多信息

项与保胎丸相关的文献（医药）

2024-08-01·BJOG: An International Journal of Obstetrics & Gynaecology

Maternal and neonatal morbidity associated with Fetal Pillow® use at full dilatation caesarean: A retrospective cohort

Article

作者: Baillie-Bellew, Thea ; McKinlay, Christopher J D ; Browne, Erena ; Hill, Meghan G ; Thompson, John M D ; Sadler, Lynn C ; Harvey, Amanda D ; Alsweiler, Jane M ; Cronin, Robin

ObjectiveTo investigate associations of the Fetal Pillow® with maternal and neonatal morbidity.DesignRetrospective cohort.SettingTwo tertiary maternity units, New Zealand.Population or SampleFull dilatation singleton, term, cephalic caesarean section, with three comparisons: at Unit A (1) before versus after introduction of the Fetal Pillow® (1 Jaunary 2016–31 October 2021); (2) with versus without the Fetal Pillow® after introduction (27 July 2017–31 October 2021); and (3) between Unit A and Unit B during the same time period (1 January 2019–31 October 2021). The Fetal Pillow® is unavailable at Unit B.MethodsCases were ascertained and clinical data were extracted from electronic clinical databases and records. Outcome data were adjusted and presented as adjusted odds ratios (aOR) with 95% CI.Main Outcome MeasuresPrimary outcome “any” uterine incision extension; secondary outcomes included major extension (into adjacent structures), and a composite neonatal outcome.ResultsIn all, 1703 caesareans were included; 375 with the device and 1328 without. Uterine incision extension rates were: at Unit A before versus after introduction: 26.8% versus 24.8% (aOR 0.88, 95% CI 0.65–1.19); at Unit A with the Fetal Pillow® versus without: 26.1% versus 23.8% (aOR 1.14, 95% CI 0.83–1.57); and at Unit A versus Unit B: 24.2% versus 29.2% (aOR 0.73, 95% CI 0.54–0.99). No differences were found in major extensions, or neonatal composite outcome.ConclusionsDespite the relatively large size of this study, it could not rule out either a positive or a negative association between use of the Fetal Pillow® and uterine extensions, major uterine incision extensions, and neonatal morbidity. Randomised controlled trial evidence is required to assess efficacy.

2023-09-22·Medicine

Study on the active ingredients and mechanism of Jiaotai Pill in the treatment of primary insomnia based on network pharmacology and GEO statistics: A review

Review

作者: Guan, Ruiqian ; Shi, Qingchun ; Pan, Limin ; Wang, Yaolei

Objective:To explore the active components and mechanism of Jiaotai Pill (JTP) in the treatment of primary insomnia (PI) based on gene expression omnibus.Methods:The main active components of Jiaotai Pills were obtained by TCMSP and literature mining, and the targets of the active components of Jiaotai Pills were predicted. The targets were verified and standardized by Uniprot database. PI-related targets were obtained from GeneCards, OMIM, DrugBank, PharmGKB, and TTD databases. Obtaining an intersection action target point of the Jiaotai pill and the PI by using a Venny diagram; Gene chip data (GSE208668) was downloaded from gene expression omnibus database, and then gene probe enrichment analysis (GSEA) was used to screen the differentially expressed genes between PI patients and normal controls, and molecular docking was used to virtually verify the screened differentially expressed genes with potential active compounds.Results:21 active components and 263 potential targets of Jiaotai Pill were screened by database analysis and literature mining, 112 of which were intersected with PI. Molecular docking results showed that quercetin, EGCG, kaempferol, R-kanatin, stigmasterol, berberine and other core active components had good docking activity with related differential genes.Conclusion:Jiaotai Pill can regulate the release of inflammatory factors through multiple active ingredients, multiple disease targets, multiple biological pathways and multiple pathways to achieve the purpose of treating PI, which provides a theoretical basis for the clinical treatment of PI and broadens the clinical use of Jiaotai Pill.

2023-03-31·Medicine

Study on the active ingredients and mechanism of action of Jiaotai Pill in the treatment of type 2 diabetes based on network pharmacology: A review

Review

作者: Chen, Xiaona ; Du, Lin ; Liu, Chenggang ; Guan, Yuxin ; Li, Yunfang ; Yang, Zhao

To explore the potential active ingredients and related mechanisms of Jiaotai Pill in the treatment of Type 2 diabetes mellitus (T2DM) based on network pharmacology and molecular docking. The main active components of Jiaotai Pills were obtained by TCMSP and BATMAN-TCM database combined with literature mining, and the targets of the active components of Jiaotai Pills were predicted by reverse pharmacophore matching (PharmMapper) method. Verifying and normalizing the obtained action targets by using a Uniprot database. Obtaining T2DM related targets through GeneCards, the online mendelian inheritance in man, DrugBank, PharmGKB and therapeutic target databases, constructing a Venn diagram by using a Venny 2.1 online drawing platform to obtain the intersection action targets of Jiaotai pills and T2DM, and the protein–protein interaction network was constructed by String platform. Bioconductor platform and R language were used to analyze the function of gene ontology and the pathway enrichment of Kyoto Encyclopedia of Genes and Genomes. A total of 21 active components and 262 potential targets of Jiaotai Pill were screened by database analysis and literature mining, including 89 targets related to T2DM. Through gene ontology functional enrichment analysis, 1690 biological process entries, 106 molecular function entries and 78 cellular component entries were obtained. Seven pathways related to T2DM were identified by Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Jiaotai Pill can achieve the purpose of treating T2DM through multiple active ingredients, multiple disease targets, multiple biological pathways and multiple pathways, which provides a theoretical basis for the clinical treatment of T2DM by Jiaotai Pill.

项与保胎丸相关的新闻（医药）

2023-01-19

·PRNewswire

The National Institute for Health and Care Excellence Recommends Fetal Pillow® As Standard Arrangements

Updated Guidance Reflects Real World Impact of Technology TRUMBULL, Conn., Jan. 19, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, today shared that the National Institute for Health and Care Excellence (NICE) recommended Fetal Pillow to be used under standard arrangements during delivery if a baby's head becomes stuck in the pelvis. NICE provides national guidance and advice to improve health and social care in the United Kingdom by putting science and evidence at the heart of healthcare decision making. NICE is an executive non-departmental public body, sponsored by the Department of Health and Social Care. "NICE's evidence-based guidance recognizes that there is sufficient data for the safe and effective use of Fetal Pillow. This recommendation will aid clinicians in emergent situations during the second stage of labor that require a cesarean section," said Dr. Vrunda Desai, VP of Medical Affairs, CooperSurgical. "We have seen meaningful results from the use of Fetal Pillow, including on average, a one-day reduction in length of hospital stays for the patient, as well as a 20-minute reduction in operating time for the physician."1 When asked, 97% of U.S. physicians in the study* responded that they would recommend the use of Fetal Pillow to others.2 Fetal Pillow is a balloon cephalic elevation device for use in cesarean sections performed during the second stage of labor (over 37 weeks). It was created to elevate the fetal head and facilitate delivery of the fetus in women requiring a cesarean at full dilation, or those requiring a cesarean after a failed instrumental vaginal delivery.3 Fetal Pillow is inserted during patient preparation for a cesarean section and inflated with saline to elevate the fetal head.4 The device allows for a significant shift from the expected difficulty in delivering the fetal head to an actual ease of delivery.1 "NICE's evidence-based recommendation will help drive more widespread use of Fetal Pillow, a device that has been shown to reduce both maternal and fetal morbidity,"1,5 stated Holly Sheffield, President, CooperSurgical. "Our work to showcase the real-world results with Fetal Pillow over the last decade, will now help to elevate the standard of care for mothers and babies across the United Kingdom. This is a true testament to CooperSurgical's commitment to a world with healthy women, babies, and families." To learn more about CooperSurgical, please visit IMPORTANT SAFETY INFORMATION Fetal Pillow is indicated to elevate the fetal head and facilitate delivery of the fetus in women >37 weeks gestation undergoing cesarean section at full dilation (with or without an instrumental delivery). The Fetal Pillow is contraindicated in the presence of an active genital infection. The safety and effectiveness of Fetal Pillow has not been established in the following: previous cesarean section, <37 weeks gestation, non-vertex presentation, intrauterine fetal death, pregnancy induced hypertension, intrauterine growth retardation, diabetes, major congenital abnormalities, chorioamnionitis, and multiple gestations. For detailed benefit and risk information, please consult Instructions for Use. About CooperSurgical CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options. CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's healthcare clinicians. More information can be found at . About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies, and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit . Contact: CooperSurgical EvolveMKD [email protected] *n=51 1 Seal SL, Dey A, Barman SC, Kamilya G, Mukherji J, Onwude JL. Randomized controlled trial of elevation of the fetal head with a fetal pillow during cesarean delivery at full cervical dilatation. Int J Gynaecol Obstet. 2016;133(2):178-182. 2 Lassey SC, Little SE, Saadeh M, et al. Cephalic Elevation Device for Second-Stage Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2020;135(4):879-884. 3 FDA Approval Letter - July 27, 2017 4 Fetal Pillow – Instructions for Use 5 Seal, S.L., Dey, A., Barman, S.C., Kamilya, G., Mukherji J. Does elevating the fetal head prior to delivery using a fetal pillow reduce maternal and fetal complications in a full dilatation caesarean section? A prospective study with historical controls. J Obstet Gynaecol. 2014;34(3):241-244. © 2022 CooperSurgical, Inc. Fetal Pillow is a registered trademark of CooperSurgical. All Rights Reserved C-US-FET-000071 12/22 Logo - SOURCE CooperSurgical®

100 项与保胎丸相关的药物交易

登录后查看更多信息